 |
PDBsum entry 6jvq
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of human mth1 in complex with compound mi1025
|
|
Structure:
|
 |
7,8-dihydro-8-oxoguanine triphosphatase. Chain: a, b. Synonym: 2-hydroxy-datp diphosphatase,8-oxo-dgtpase,nucleoside diphosphate-linked moiety x motif 1,nudix motif 1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: nudt1, mth1. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.203
|
R-free:
|
0.266
|
|
|
Authors:
|
 |
C.Peng,Y.H.Li,Y.S.Cheng
|
|
Key ref:
|
 |
C.Peng
et al.
(2021).
Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Bioorg Chem,
110,
104813.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
17-Apr-19
|
Release date:
|
28-Oct-20
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P36639
(8ODP_HUMAN) -
Oxidized purine nucleoside triphosphate hydrolase from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
156 a.a.
154 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.6.1.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.3.6.1.56
- 2-hydroxy-dATP diphosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
2-oxo-dATP + H2O = 2-oxo-dAMP + diphosphate + H+
|
 |
 |
 |
 |
 |
2-oxo-dATP
|
+
|
H2O
|
=
|
2-oxo-dAMP
|
+
|
diphosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Chem
110:104813
(2021)
|
|
PubMed id:
|
|
|
|
|
| |
|
Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
|
|
C.Peng,
Y.H.Li,
C.W.Yu,
Z.H.Cheng,
J.R.Liu,
J.L.Hsu,
L.W.Hsin,
C.T.Huang,
H.F.Juan,
J.W.Chern,
Y.S.Cheng.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
MutT Homolog 1 (MTH1) has been proven to hydrolyze oxidized nucleotide
triphosphates during DNA repair. It can prevent the incorporation of wrong
nucleotides during DNA replication and mitigate cell apoptosis. In a cancer
cell, abundant reactive oxygen species can lead to substantial DNA damage and
DNA mutations by base-pairing mismatch. MTH1 could eliminate oxidized dNTP and
prevent cancer cells from entering cell death. Therefore, inhibition of MTH1
activity is considered to be an anti-cancer therapeutic target. In this study,
high-throughput screening techniques were combined with a fragment-based library
containing 2,313 compounds, which were used to screen for lead compounds with
MTH1 inhibitor activity. Four compounds with MTH1 inhibitor ability were
selected, and compound MI0639 was found to have the highest effective
inhibition. To discover the selectivity and specificity of this action, several
derivatives based on the MTH1 and MI0639 complex structure were synthesized. We
compared 14 complex structures of MTH1 and the various compounds in combination
with enzymatic inhibition and thermodynamic analysis. Nanomolar-range
IC50 inhibition abilities by enzyme kinetics and Kd values
by thermodynamic analysis were obtained for two compounds, named MI1020 and
MI1024. Based on structural information and compound optimization, we aim to
provide a strategy for the development of MTH1 inhibitors with high selectivity
and specificity.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |